TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $5,056,473 | +50.2% | 3,370,982 | 0.0% | 1.31% | +50.3% |
| Q4 2022 | $3,367,611 | -44.5% | 3,370,982 | 0.0% | 0.87% | -39.2% |
| Q3 2022 | $6,068,000 | -37.9% | 3,370,982 | 0.0% | 1.44% | -47.1% |
| Q2 2022 | $9,776,000 | +5.1% | 3,370,982 | 0.0% | 2.72% | +8.8% |
| Q1 2022 | $9,304,000 | -40.8% | 3,370,982 | 0.0% | 2.50% | -12.8% |
| Q4 2021 | $15,709,000 | -45.2% | 3,370,982 | 0.0% | 2.86% | -35.6% |
| Q3 2021 | $28,687,000 | -48.1% | 3,370,982 | 0.0% | 4.45% | -51.0% |
| Q2 2021 | $55,318,000 | -25.7% | 3,370,982 | 0.0% | 9.09% | -2.8% |
| Q1 2021 | $74,431,000 | -64.3% | 3,370,982 | -50.0% | 9.35% | -48.1% |
| Q4 2020 | $208,528,000 | +204.4% | 6,741,964 | +100.0% | 18.01% | +9.1% |
| Q3 2020 | $68,498,000 | +32.3% | 3,370,982 | 0.0% | 16.50% | +19.9% |
| Q2 2020 | $51,778,000 | +98.5% | 3,370,982 | 0.0% | 13.77% | -13.6% |
| Q1 2020 | $26,091,000 | -45.8% | 3,370,982 | 0.0% | 15.94% | -6.6% |
| Q4 2019 | $48,138,000 | – | 3,370,982 | – | 17.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |